期刊
CELL REPORTS MEDICINE
卷 1, 期 2, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.xcrm.2020.100016
关键词
-
资金
- Institut National de la Sante et de la Recherche Medicale (INSERM), France
- Centre National de la Recherche Scientifique (CNRS), France
- Sorbonne Universite, France
- Universite de Paris, France
- Institut Pasteur, France
- Agence Nationale de la Recherche, France [ANR-19-CE17-0021]
- COVID emergency fund from Universite de Paris
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as of May 8, 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments, such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation, and passive viral neutralization not only reduce inflammation, inflammationassociated lung damage, or viral load but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation, both of which are limited resources.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据